Early Angiotensin II in the Emergency Department
Recruiting · Phase 4 · NCT06693726
Conditions: Septic Shock
At a glance
- Research payments reported, 2025
- $9,820
- U.S. investigators named
- 0
- Sites paid
- 1
- Planned or actual enrollment
- 20
About the trial
- Sponsor
- Brett A Faine
- Tested
- Angiotensin II Infusion (drug)
- Dates
- Started 2025-04-01; completion 2027-01-30
- Results posted
- Not yet
This pilot study will enroll 20 patients with septic shock and require emergent vasopressor support in the emergency department (ED). The primary objective of the study is to determine the feasibility of early peripheral administration of angiotensin II for treatment of septic shock in the ED
From ClinicalTrials.gov, last updated 2026-09-02. Full record, eligibility and contacts (opens in a new tab)
Industry funding
La Jolla Pharmaceutical Company reported $9,820 in research payments for this study in 2025 (1 payments).
Products named: Giapreza
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
Sites paid to run it
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.